NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
Clinical Trials
10 trialsNCT01463891 2023-07-24
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Eisai Inc.
Completed
NCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT02551263 2021-06-11
E-SPEC
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Completed
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT03058406 2020-04-06
HAL03T
Eisai Inc.
Completed
NCT02393287 2019-05-09
ReProLine
Institut Cancerologie de l'Ouest
Completed
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03437083 2019-01-25
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Eisai Inc.
Completed
NCT03245112 2017-08-16
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
Chang Gung Memorial Hospital
Unknown